Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
Yoshioka
Keiji
K
Yoshida
Toshihide
T
Yoshikawa
Toshikazu
T
D052242:Adiponectin; D001786:Blood Glucose; D002219:Carbamates / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011506:Proteins / Q000378:metabolism*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D052242:Adiponectin; D001786:Blood Glucose; D002219:Carbamates; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D036341:Intercellular Signaling Peptides and Proteins; D010880:Piperidines; D011506:Proteins; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide; C057619:glimepiride